Two Biotechs Gear Up for Nasdaq Debut

Two weeks after announcing plans for initial public offerings, Gyroscope Therapeutics and Talaris Therapeutics have now set the terms for their debut on the Nasdaq. Both companies expect to secure more than $100 million from their IPOs.